You are here

Article info

Article menu

Download PDFPDF

Miscellaneous
Viewpoint
Assessment of type I interferon response in routine practice in France in 2022

Authors

  • Anais Nombel Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, FranceInternational Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France PubMed articlesGoogle scholar articles
  • Anne Perrine Foray Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France PubMed articlesGoogle scholar articles
  • Lorna Garnier Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France PubMed articlesGoogle scholar articles
  • Christine Lombard Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France PubMed articlesGoogle scholar articles
  • Eric Hachulla Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), Université de Lille, CHU Lille, Lille, France PubMed articlesGoogle scholar articles
  • Brigitte Bader-Meunier Department of Paediatric Hematology-Immunology and Rheumatology, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Necker-Enfants Malades Hospital, AP-HP, Paris, France PubMed articlesGoogle scholar articles
  • Sophie Georgin-Lavialle Service Médecine Interne, Centre de référence des maladies autoinflammatoires et des amyloses (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France PubMed articlesGoogle scholar articles
  • Isabelle Melki General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré Mother-Child University Hospital, AP-HP, Paris, France PubMed articlesGoogle scholar articles
  • Thierry Walzer International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France PubMed articlesGoogle scholar articles
  • Alexandre Belot International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, FrancePediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère Enfant, Hospices Civils de Lyon, Lyon, France PubMed articlesGoogle scholar articles
  • Sebastien Viel Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, FranceInternational Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sebastien Viel; sebastien.viel{at}inserm.fr; Dr Alexandre Belot; alexandre.belot{at}chu-lyon.fr
View Full Text

Citation

Nombel A, Foray AP, Garnier L, et al
Assessment of type I interferon response in routine practice in France in 2022
RMD Open 2023;9:e003211. doi: 10.1136/rmdopen-2023-003211

Publication history

  • Received April 4, 2023
  • Accepted May 22, 2023
  • First published June 15, 2023.
Online issue publication 
June 15, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.